GeoVax Labs Inc GOVX.OQ GOVX.O is expected to show a fall in quarterly revenue when it reports results on March 25 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for GeoVax Labs Inc is for a loss of $6.17 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GeoVax Labs Inc is $231.25, about 15,631.3% above its last closing price of $1.47
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -6.54 | -6.62 | -7.75 | Missed | -17 |
Jun. 30 2025 | -9.71 | -9.00 | -8.75 | Beat | 2.8 |
Mar. 31 2025 | -14.23 | -16.67 | -11.25 | Beat | 32.5 |
Dec. 31 2024 | -19.20 | -7.50 | Beat | 60.9 | |
Sep. 30 2024 | -35.76 | -36.94 | -22.75 | Beat | 38.4 |
Jun. 30 2024 | -62.82 | -84.12 | -49.75 | Beat | 40.9 |
Mar. 31 2024 | -1.39 hundred | -1.39 hundred | -61.75 | Beat | 55.6 |
Dec. 31 2023 | -56.84 | -69.42 | -3.40 hundred | Missed | -389.8 |
This summary was machine generated March 23 at 20:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)